Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Immunoglobulin heavy chain variable ( IGHV) testing has become an important prognostic and therapeutic factor in chronic ...

In vitro studies have suggested that BTKi therapy can suppress NOTCH1 activation via B-cell receptor–NOTCH1 interactions, providing a mechanistic rationale for these clinical results.

Nomograms demonstrated strong predictive performance, with C-indexes around 0.70 to 0.72 and 5- and 10-year areas under the curve ranging from 0.713 to 0.759 in training and validation cohorts.

"We present the largest study to date describing the racial and ethnic identity of American CLL patients in the era of modern therapies, and the largest study analyzing the general treatment patterns ...

The goal of CLL management is to maintain the best quality of life and treat only when patients become symptomatic from their disease. 7,8 Unlike other hematologic malignancies, CLL is a long-term, ...

Chronic lymphocytic leukemia (CLL) starts in bone marrow, the soft inner part of your bones. There are some key differences that set CLL apart from other types of leukemia, such as ALL (acute ...

Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

Test detects genetic abnormalities to aid in the prediction of chronic lymphocytic leukemia patient survival. Abbott received 510k clearance for an in vitro diagnostic test to aid in determining the ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...